تداخلات روسوفاستاتين

Do not use erythromycin concomitantly with HMG CoA reductase inhibitors (statins) that are extensively metabolized by CYP 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see PRECAUTIONS - Drug Interactions ). (نشرة إريثرومايسين، موانع الاستعمال)

Lipid-modifying Agents: HMG-CoA Reductase Inhibitors: lovastatin simvastatin ↑ lovastatin ↑ simvastatin Coadministration with lovastatin or simvastatin is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. atorvastatin ↑ atorvastatin Initiate atorvastatin with the lowest starting dose of atorvastatin and titrate… (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (نشرة إيزيتيميب، موانع الاستعمال)

HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) (نشرة بوساكونازول، موانع الاستعمال)

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis The concomitant use of rosuvastatin tablets with cyclosporine or gemfibrozil is not recommended. rosuvastatin tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration ( 2.6 )] . (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Lipid Modifying Agents: HMG-CoA reductase inhibitors : lovastatin, simvastatin ↑ lovastatin ↑ simvastatin Co-administration is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. atorvastatin, pravastatin, rosuvastatin ↑ HMG-CoA reductase inhibitors Co-administration of PREZISTA/ritonavir with HMG-Co A reductase inhibitors… (نشرة دارونافير، التداخلات الدوائية)

Dosage recommendations with atorvastatin or rosuvastatin are as follows: atorvastatin dosage should not exceed 20 mg/day rosuvastatin dosage should not exceed 20 mg/day Other lipid modifying agents: lomitapide ↑ lomitapide Co-administration is contraindicated due to potential for markedly increased transaminases associated with increased plasma concentrations… (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

• Statins: Avoid simvastatin doses greater than 10 mg daily. (نشرة درونيدارون، التداخلات الدوائية)

…Antifungal: voriconazole ○ Anti-gout: colchicine ○ Antipsychotics: lurasidone, pimozide ○ Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine ○ GI Motility Agent: cisapride ○ HMG-CoA Reductase Inhibitors: lovastatin, simvastatin ○ Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ○ Non-opioid Analgesic (selective blocker of Na v 1.8 sodium… (نشرة ريتونافير، موانع الاستعمال)

Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin Tablets Sofosbuvir/ velpatasvir/ voxilaprevir or Ledipasvir/ sofosbuvir Prevention or Management: Avoid concomitant use with rosuvastatin tablets. (نشرة روسوفاستاتين، التداخلات الدوائية)

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis The concomitant use of rosuvastatin tablets with cyclosporine or gemfibrozil is not recommended. rosuvastatin tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration ( 2.6 )] . (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )]. (نشرة كلاريثرومايسين، موانع الاستعمال)

Myopathy Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with ketoconazole tablets (see PRECAUTIONS: Drug Interactions ). (نشرة كيتوكونازول، موانع الاستعمال)

…Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of Nav1.8 sodium… (نشرة لوبينافير وريتونافير، موانع الاستعمال)

Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin Tablets Sofosbuvir/ velpatasvir/ voxilaprevir or Ledipasvir/ sofosbuvir Prevention or Management: Avoid concomitant use with rosuvastatin tablets. (نشرة روسوفاستاتين، التداخلات الدوائية)

…lurasidone, pimozide • Benign prostatic hyperplasia agents: silodosin • Cardiovascular agents: eplerenone, ivabradine • Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants:… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

Additional Anti-Viral Medications Prevention or Management: • Simeprevir • Dasabuvir/ombitasvir/paritaprevir/ritonavir • Elbasvir/grazoprevir • Sofosbuvir/velpatasvir • Glecaprevir/pibrentasvir • Atazanavir/ritonavir • Lopinavir/ritonavir Initiate with rosuvastatin tablets 5 mg once daily, and do not exceed a dosage of rosuvastatin tablets 10 mg once daily. (نشرة روسوفاستاتين، التداخلات الدوائية)

…concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib,… (نشرة إلترومبوباغ، التداخلات الدوائية)

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations ( 8.7 )]. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Mechanism and Clinical Effect(s) Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% [ see Clinical Pharmacology ( 12.3 ) ]. (نشرة روسوفاستاتين، التداخلات الدوائية)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy. (نشرة أوباداسيتينيب، التحذيرات والاحتياطات)

Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin Tablets Antacids Prevention or Management In patients taking an antacid, administer rosuvastatin tablets at least 2 hours before the antacid. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

The risk is also greater in patients taking VYTORIN 80 mg daily compared with patients taking lower VYTORIN dosages and compared with patients using other statins with similar or greater LDL-C-lowering efficacy [see Adverse Reactions (6.1) ] . (نشرة إيزيتيميب وسيمفاستاتين، التحذيرات والاحتياطات)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (نشرة إيكوسابنت إيثيل، التحذيرات والاحتياطات)

Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see Clinical Pharmacology ( 12.3 ) ] Intervention: Use the lowest effective dose of rosuvastatin (see prescribing information of rosuvastatin for additional information on recommended dosing). (نشرة إيلوكسادولين، التداخلات الدوائية)

Interactions With Drugs Metabolized by CYP3A4 Gleevec will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window. (نشرة إيماتينيب، التداخلات الدوائية)

Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (نشرة بازوبانيب، التحذيرات والاحتياطات)

Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1) ]. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

HMG-CoA Reductase Inhibitors: lovastatin simvastatin ↑ lovastatin ↑ simvastatin Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g., myopathy). (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin Tablets Antacids Prevention or Management In patients taking an antacid, administer rosuvastatin tablets at least 2 hours before the antacid. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Teriflunomide Prevention or Management: In patients taking teriflunomide, do not exceed a dosage of rosuvastatin tablets 10 mg once daily. (نشرة روسوفاستاتين، التداخلات الدوائية)

Ticagrelor Prevention or Management: In patients taking ticagrelor, do not exceed a dosage of rosuvastatin tablets 20 mg once daily. (نشرة روسوفاستاتين، التداخلات الدوائية)

Fenofibrates (e.g., fenofibrate and fenofibric acid) Prevention or Management: Consider if the benefit of using fibrates concomitantly with rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. (نشرة روسوفاستاتين، التداخلات الدوائية)

In patients who receive Daptomycin for Injection, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with Daptomycin for Injection. (نشرة دابتومايسين، التحذيرات والاحتياطات)

The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvastatin and lovastatin. (نشرة دانازول، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. (نشرة ديسوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing). (نشرة رولابيتانت، التداخلات الدوائية)

Decrease exposure Selective 5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day),… (نشرة ريفامبيسين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

During sirolimus therapy with or without cyclosporine, patients should be monitored for elevated lipids, and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects, as described in the respective labeling for these agents. (نشرة سيروليموس، التحذيرات والاحتياطات)

The risk is also greater in patients taking an 80 mg daily dosage of ZOCOR compared with patients taking lower ZOCOR dosages and compared with patients using other statins with similar or greater LDL-C-lowering efficacy [see Adverse Reactions (6.1) ] . (نشرة سيمفاستاتين، التحذيرات والاحتياطات)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Lipid Modifying Agents: HMG-CoA reductase inhibitors : Atorvastatin a Lovastatin, simvastatin Other lipid modifying agents : Lomitapide ↑Atorvastatin ↑Lovastatin ↑Simvastatin ↑Lomitapide Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 20 mg/day. (نشرة فوسامبرينافير، التداخلات الدوائية)

Febuxostat Prevention or Management: In patients taking febuxostat, do not exceed a dosage of rosuvastatin tablets 20 mg once daily. (نشرة روسوفاستاتين، التداخلات الدوائية)

Fenofibrates (e.g., fenofibrate and fenofibric acid) Prevention or Management: Consider if the benefit of using fibrates concomitantly with rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1) ]. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Thus, clinicians considering combined therapy of quinine sulfate with atorvastatin or other HMG-CoA reductase inhibitors ("statins") that are CYP3A4 substrates (e.g., simvastatin, lovastatin) should carefully weigh the potential benefits and risks of each medication. (نشرة كينين، التداخلات الدوائية)

Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (نشرة لانثانوم، التداخلات الدوائية)

However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin. (نشرة لوفاستاتين، التداخلات الدوائية)

Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking ARAVA. (نشرة ليفلونوميد، التداخلات الدوائية)

Substances increasing the systemic exposure of CHCs: Co-administration of atorvastatin or rosuvastatin and CHCs containing ethinyl estradiol increase systemic exposure of ethinyl estradiol by approximately 20 to 25 percent. (نشرة ليفونورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

HMG-CoA Reductase Inhibitors: lovastatin simvastatin ↑ lovastatin ↑ simvastatin Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g., myopathy). (نشرة ليناكابافير، التداخلات الدوائية)

Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin Tablets Antacids Prevention or Management In patients taking an antacid, administer rosuvastatin tablets at least 2 hours before the antacid. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

Substances increasing the plasma concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20-25%. (نشرة نورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Substances increasing the plasma concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20-25%. (نشرة نورجيستيمات وإيثينيل إستراديول، التداخلات الدوائية)

Substances Increasing the Plasma Concentrations of CHCs Co-administration of atorvastatin or rosuvastatin and certain CHCs containing EE increase AUC values for EE by approximately 20% to 25%. (نشرة نوريلجيسترومين وإيثينيل إستراديول، التداخلات الدوائية)

Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions ( 7.1) ]. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations… (نشرة نيفازودون، التداخلات الدوائية)

Table 7: Rosuvastatin Tablet Effects on Other Drugs Warfarin Prevention or Management: In patients taking warfarin, obtain an INR before starting rosuvastatin tablets and frequently enough after initiation, dosage titration or discontinuation to ensure that no significant alteration in INR occurs. (نشرة روسوفاستاتين، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H 2 blockers [see Clinical Pharmacology (12.3) ] . (نشرة براسوغريل، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

HMG-CoA Reductase Inhibitors The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis. (نشرة فيراباميل، التداخلات الدوائية)

…acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant… (نشرة فيناستيريد، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة روسوفاستاتين، التحذيرات والاحتياطات)

Should treatment with any HMG-CoA reductase inhibitor (a lipid lowering agent) be needed to treat lipid elevations, evaluate the potential for a drug-drug interaction before initiating therapy as certain HMG-CoA reductase inhibitors are metabolized by the CYP3A4 pathway [see Drug Interactions ( 7.1 )] . (نشرة نيلوتينيب، التحذيرات والاحتياطات)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (نشرة بريكسبيبرازول، التداخلات الدوائية)

Based on these data, ISENTRESS is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein (e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton pump inhibitors and anti-erectile dysfunction agents). (نشرة رالتيغرافير، التداخلات الدوائية)